Who are Ibrance's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Kisqali, Abemaciclib + Aromatase Inhibitor, Abemaciclib + Fulvestrant, Palbociclib, target treatment, Palbociclib PD-0332991.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ibrance.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Ibrance — Competitive Intelligence Brief

Ibrance (Palbociclib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CDK4/6 inhibitor. Area: Oncology.

marketed CDK4/6 inhibitor Cyclin-dependent kinases 4 and 6 (CDK4/6) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ibrance (Palbociclib) — Pfizer. Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ibrance TARGET	Palbociclib	Pfizer	marketed	CDK4/6 inhibitor	Cyclin-dependent kinases 4 and 6 (CDK4/6)	2015-01-01
Kisqali	ribociclib	Novartis	marketed	CDK4/6 inhibitor; aromatase inhibitor	Cyclin-dependent kinase (CDK) 4 and 6; aromatase enzyme	2017-01-01
Abemaciclib + Aromatase Inhibitor	Abemaciclib + Aromatase Inhibitor	Prof. Wolfgang Janni	marketed	CDK4/6 inhibitor + Aromatase inhibitor combination	CDK4/6 + Aromatase
Abemaciclib + Fulvestrant	Abemaciclib + Fulvestrant	Prof. Wolfgang Janni	marketed	CDK4/6 inhibitor + estrogen receptor antagonist	CDK4/6 and estrogen receptor (ER)
Palbociclib	palbociclib	Pfizer Inc.	marketed	CDK4/6 inhibitor	Cyclin-dependent kinases 4 and 6 (CDK4/6)
target treatment	target treatment	Institut Bergonié	marketed	CDK4/6 inhibitor	CDK4/6
Palbociclib PD-0332991	Palbociclib PD-0332991	GBG Forschungs GmbH	phase 3	CDK4/6 inhibitor	CDK4/6

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CDK4/6 inhibitor class)

AstraZeneca · 1 drug in this class
Centre Leon Berard · 1 drug in this class
Draig Therapeutics Ltd · 1 drug in this class
Fujian Cancer Hospital · 1 drug in this class
GBG Forschungs GmbH · 1 drug in this class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Institut Bergonié · 1 drug in this class
Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class
Kartos Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ibrance — Competitive Intelligence Brief. https://druglandscape.com/ci/ibrance. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab